Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty

被引：11
作者：
Sheikh, Virginia [1 ]
Murray, Jeffrey S. [1 ]
Sherwat, Adam [1 ]
机构：
[1] US FDA, Div Antiviral Prod, Off Antimicrobial Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 07期
关键词：
D O I：
10.1056/NEJMp1808729
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：605 / 607
页数：4
相关论文
共 4 条
  • [1] FDA, 2015, GUID IND HUM IMM VIR
  • [2] FDA, 2015, GUID IND DRAFT GUID
  • [3] The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs
    Murray, JS
    Elashoff, MR
    Iacono-Connors, LC
    Cvetkovich, TA
    Struble, KA
    [J]. AIDS, 1999, 13 (07) : 797 - 804
  • [4] Antiretroviral therapies for treatment-experienced patients: current status and research challenges
    Struble, K
    Murray, J
    Cheng, B
    Gegeny, T
    Miller, V
    Gulick, R
    [J]. AIDS, 2005, 19 (08) : 747 - 756
1